Q-omics provides the consensus-scored IFI27L2 profile across patient tissues and cancer cell-line models. IFI27L2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IFI27L2 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, IFI27L2 RNA expression shows 18,836 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, and THYM as cancer lineages where IFI27L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFI27L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFI27L2 survival associations across molecular data types. IFI27L2 RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFI27L2 RNA expression–survival associations across cancer types. High IFI27L2 expression shows unfavorable associations in HNSC, ACC, UCS, LAML and THYM, but favorable associations in LGG. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IFI27L2 RNA expression.
This table summarizes IFI27L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IFI27L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFI27L2 shows lower tumor expression in LUAD and UCEC and higher tumor expression in HNSC, KIRC, LIHC and KIRP. The HNSC box plot shows higher IFI27L2 RNA expression in tumor versus normal tissue (log2 FC = +1.208, t-test p < 0.001).
This table shows molecular features associated with IFI27L2 in patient tissues and cancer cell lines. In patient samples, IFI27L2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IFI27L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
